A Phase II Controlled Trial of a Single ProHema-CB unit (Ex Vivo CXCR4-Upregulated CD34+ Hematopoietic Progenitor Cells, Cord Blood) As Part of a Double Umbilical Cord Blood Transplant Following Myeloablative Conditioning For Patients Age 15-65 Years With Hematologic Malignancies
The purpose of this study is to find out how well subjects who receive a transplant with an investigational cord blood product respond to treatment.
Cancers of the blood and bone marrow in patients who are planning to undergo a double umbilical cord blood stem cell transplant.
--Your doctor has determined that allogeneic stem cell transplant is an appropriate treatment for your disease.
--Patients with cancers of the blood for whom a suitable related or unrelated adult stem cell donor is not available.
--Between the ages of 15 and 55
--Other criteria as dictated by the study protocol and the judgment of the study's Principal Investigator.
15 - 65
Healthy Volunteers Needed
Duration of Participation
Fate Therapeutics, Inc.